News - Cardio-vascular, Licensing

Filter

Current filters:

Cardio-vascularLicensing

Popular Filters

1 to 25 of 59 results

Ligand licenses five programs to Viking Therapeutics

23-05-2014

US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Cardiome out-licenses Aggrastat in select European markets

20-05-2014

Canada-based Cardiome Pharma has signed an agreement with AOP Orphan Pharmaceuticals, headquartered in…

AggrastatAOP OrphanAustriaBrinavessCardio-vascularCardiome PharmaHungaryLicensingPharmaceutical

Ligand signs dyslipidemia related diseases accord with AstraZeneca unit

14-05-2014

US drugmaker Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration…

AstraZenecaCardio-vascularLicensingLigand PharmaceuticalsOmthera PharmaceuticalsPharmaceuticalResearch

AstraZeneca signs deals for antibiotic and cardiovascular research

AstraZeneca signs deals for antibiotic and cardiovascular research

28-01-2014

Anglo-Swedish drug major AstraZeneca has entered into further collaborations to expand its research base,…

Antibiotics and Infectious diseasesAstraZenecaCardio-vascularFOB SynthesisLicensingPharmaceuticalResearch

Capricor Therapeutics and Janssen collaborate on cell therapy program

Capricor Therapeutics and Janssen collaborate on cell therapy program

07-01-2014

California, USA-based Capricor Therapeutics says it has executed a collaboration agreement and exclusive…

BiotechnologyCAP-1002Capricor TherapeuticsCardio-vascularJanssen BiotechJohnson & JohnsonLicensing

AstraZeneca and Shionogi settle Crestor arbitration

AstraZeneca and Shionogi settle Crestor arbitration

26-12-2013

Anglo-Swedish drug major AstraZeneca revealed yesterday (December 26) the full resolution of arbitration…

Asia-PacificAstraZenecaCardio-vascularCrestorGlobalLicensingPharmaceuticalShionogi

Oxygen Biotherapeutics signs agreement to acquire Phase III cardiac drug from Phyxius Pharma

22-10-2013

US drug developer Oxygen Biotherapeutics has signed a Definitive Agreement to acquire certain assets…

Cardio-vascularLevosimendanLicensingMergers & AcquisitionsNorth AmericaOxygen BiotherapeuticsPharmaceutical

Xention and Servier sign up for cardiovascular collaboration

Xention and Servier sign up for cardiovascular collaboration

02-10-2013

Xention and Servier have entered into a multi-year agreement for the development and commercialization…

BiotechnologyCardio-vascularLicensingServierXention

Cardiome in deal for commercialization of Brinavess in Israel

18-09-2013

Canada-based Cardiome Pharma (TSX: COM) has entered into an agreement with Tzamal Medical to sell and…

BrinavessCardio-vascularCardiome PharmaLicensingPharmaceuticalRest of the WorldTzamal Medical

Takeda out-licenses Edarbi and Edarbyclor

13-09-2013

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into a license, development and…

Arbor PharmaceuticalsCardio-vascularEdarbiEdarbyclorLicensingNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Sanofi US in deal to commercialize PA8140/PA32540

04-09-2013

The US subsidiary of French drug major Sanofi (Euronext: SAN) has entered into a deal with US drugmaker…

AspirinCardio-vascularGastro-intestinalsLicensingNorth AmericaOmeprazolePharmaceuticalPozenSanofi

Amgen's US deal with Servier cleared

13-08-2013

USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, and privately-held French…

AmgenBiotechnologyCardio-vascularLicensingNorth AmericaPharmaceuticalProcoralanServier

Forest agrees another license deal for Bystolic

22-07-2013

US drugmaker Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings have reached a settlement…

Amerigen PharmaceuticalsBystolicCardio-vascularForest LaboratoriesGenericsLicensingNorth AmericaPharmaceutical

Amgen gains rights to Servier's heart drugs ivabradine and S38844

10-07-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has entered a new collaboration…

AmgenBiotechnologyCardio-vascularEuropeivabradineLicensingNorth Americaomecamtiv mecarbilPharmaceuticalS38844Servier

XOMA transfers perindopril franchise rights to Symplmed

08-07-2013

California, USA-based XOMA Corp (Nasdaq: XOMA) says it has transferred US development and commercialization…

Cardio-vascularLicensingMergers & AcquisitionsperindoprilPharmaceuticalServierSymplmedXOMA Corp

Pharming and SIPI collaboration includes Ruconest marketing in China

02-07-2013

Dutch biotech company Pharming Group (NYSE Euronext: PHARM) and Shanghai Institute of Pharmaceutical…

Asia-PacificBiotechnologyCardio-vascularLicensingPharmaceuticalPharmingResearchRuconestSinopharm Group

Cardiome gains European MA rights for Brinavess from Merck & Co

27-06-2013

Canada-based Cardiome Pharma (TSX: COM) has announced adoption of the decision by the European Commission…

BrinavessCardio-vascularCardiome PharmaEuropeLicensingMerck & CoPharmaceuticalRegulation

SciClone and Taiwan Liposome link up on ProFlow for China

26-06-2013

USA-based SciClone Pharmaceuticals (Nasdaq: SCLN) yesterday (June 25) has announced an agreement with…

Asia-PacificCardio-vascularLicensingPharmaceuticalProFlowSciClone PharmaTaiwan Liposome

Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis

19-06-2013

Sweden-based Athera Biotechnologies, which is 65% owned by Karolinska Development, has entered into an…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularKarolinska DevelopmentLicensing

Amgen and Cytokinetics expand omecamtiv mecarbil accord

12-06-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has expanded its strategic…

AmgenAsia-PacificBiotechnologyCardio-vascularCytokineticsLicensingomecamtiv mecarbil

Abcam in deal with Pfizer to supply compounds to researchers

12-06-2013

UK-based Abcam (AIM: ABC), a producer and distributor of protein research tools, has entered into a license…

AbcamCardio-vascularLicensingNeurologicalOncologyPfizerPharmaceuticalResearch

RedHill Biopharma views regulatory pathway for RHB-101 in CHF and hypertension

29-05-2013

Emerging Israeli biopharma company RedHill Biopharma (TASE: RDHL) says that it recently concluded a positive…

BiotechnologyCardio-vascularCarvedilolLicensingPharmaceuticalRedHill BiopharmaRegulationResearchRHB-101

SciClone gains China rights to Zensun's Neucardin

20-05-2013

USA-based SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the Company has entered into an…

Asia-PacificCardio-vascularLicensingNeucardinPharmaceuticalSciClone PharmaZensun

1 to 25 of 59 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top